Tenax Ev To Sales from 2010 to 2024

TENX Stock  USD 5.72  0.36  6.72%   
Tenax Therapeutics EV To Sales yearly trend continues to be fairly stable with very little volatility. EV To Sales is likely to outpace its year average in 2024. EV To Sales is the Enterprise Value to Sales ratio, a valuation metric used to compare the value of a company, including debt and excluding cash, to its sales revenue. View All Fundamentals
 
EV To Sales  
First Reported
2010-12-31
Previous Quarter
134.5 K
Current Value
141.2 K
Quarterly Volatility
68.5 K
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Tenax Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Tenax Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 7.2 K, Other Operating Expenses of 8.4 M or Research Development of 3.6 M, as well as many indicators such as Price To Sales Ratio of 141.3 K, Dividend Yield of 3.31 or PTB Ratio of 0.71. Tenax financial statements analysis is a perfect complement when working with Tenax Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Tenax Therapeutics Correlation against competitors.
For more information on how to buy Tenax Stock please use our How to Invest in Tenax Therapeutics guide.

Latest Tenax Therapeutics' Ev To Sales Growth Pattern

Below is the plot of the Ev To Sales of Tenax Therapeutics over the last few years. It is the Enterprise Value to Sales ratio, a valuation metric used to compare the value of a company, including debt and excluding cash, to its sales revenue. Tenax Therapeutics' EV To Sales historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Tenax Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Ev To Sales10 Years Trend
Slightly volatile
   Ev To Sales   
       Timeline  

Tenax Ev To Sales Regression Statistics

Arithmetic Mean100,400
Geometric Mean47,463
Coefficient Of Variation68.24
Mean Deviation62,263
Median149,414
Standard Deviation68,509
Sample Variance4.7B
Range148.9K
R-Value0.80
Mean Square Error1.9B
R-Squared0.63
Significance0.0004
Slope12,192
Total Sum of Squares65.7B

Tenax Ev To Sales History

2024141.2 K
2023134.5 K
2015149.4 K
2013 8670.75
2012 536.67
2011 8894.91
2010 8256.92

About Tenax Therapeutics Financial Statements

Tenax Therapeutics investors use historical fundamental indicators, such as Tenax Therapeutics' Ev To Sales, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Tenax Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
EV To Sales134.5 K141.2 K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Tenax Stock Analysis

When running Tenax Therapeutics' price analysis, check to measure Tenax Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tenax Therapeutics is operating at the current time. Most of Tenax Therapeutics' value examination focuses on studying past and present price action to predict the probability of Tenax Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tenax Therapeutics' price. Additionally, you may evaluate how the addition of Tenax Therapeutics to your portfolios can decrease your overall portfolio volatility.